SAMANTHA BARRY: Open Payments
NPI 1396297495 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$969 in 43 payments from 18 companies in 2025. Trend: 2023 $279 · 2024 $654 · 2025 $969
Food & beverage: $969
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 4 | $178 |
| ABBVIE INC. | 10 | $150 |
| Novo Nordisk Inc | 3 | $141 |
| Phathom Pharmaceuticals, Inc. | 6 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $44 |
| GENZYME CORPORATION | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Ardelyx, Inc. | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 1 | $31 |
Products named: TREMFYA, Wegovy, RINVOQ, VOQUEZNA, ENTYVIO, XIFAXAN, DUPIXENT, CAPLYTA.
Industry payments across KY — which companies pay providers there.
